JP Morgan Initiates Coverage On Enliven Therapeutics with Overweight Rating, Announces Price Target of $75

Benzinga Newsdesk www.benzinga.com Neutral 57.8%

Neg 0% Neu 57.8% Pos 0%

JP Morgan analyst Priyanka Grover initiates coverage on Enliven Therapeutics (NASDAQ:ELVN) with a Overweight rating and announces Price Target of $75.